OpenAI Acquires Orchestra Bio to Fold Drug-Development Agents Into Rosalind
OpenAI said on Oct. 20 it has acquired Orchestra Bio, a platform where scientists and program leaders delegate monitoring and tracking of drug-development studies to AI agents. Orchestra's team and technology will join Rosalind. No price was disclosed; TechCrunch says the four-year-old startup had reportedly raised about $20M as of 2025.
OpenAI is buying operational coordination for drug programs, not only molecule-level reasoning. On Tuesday, October 20, OpenAI said it has acquired Orchestra Bio, a platform where scientists and program leaders hand off the monitoring and tracking of drug-development studies and campaigns to AI agents. Orchestra's team and technology will join Rosalind, OpenAI's life-sciences models and tools, including GPT-Rosalind and Rosalind Workbench. OpenAI gave no price.
TechCrunch reports the four-year-old startup had reportedly raised about $20 million as of 2025 from backers including Andreessen Horowitz, Atria and 8VC. OpenAI names Novo Nordisk and Moderna as Rosalind partners. We covered GPT-Rosalind capabilities and Rosalind biodefense trusted access earlier.
Limits
- Acquisition price undisclosed.
- Prior funding figure is TechCrunch's "reportedly."